AI-generated from publicly available materials.London-based startup Pharosyn has secured €2.5 million to enhance its AI-driven platform aimed at improving competitive intelligence in the pharmaceutical sector.
The funding round was spearheaded by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance. This investment comes at a time of significant growth in AI and data infrastructure funding for pharmaceutical and biotech companies, with approximately €75.3 million raised across similar initiatives in 2026 alone.
Pharosyn, founded by Stephen Cowley and Joshua Hampson, aims to provide tailored strategic insights by monitoring clinical, regulatory, and commercial data sources. The platform is designed to integrate deeply within pharmaceutical teams, enhancing decision-making processes across various functions including market research and resource allocation. According to Hampson, the product is continuously evolving, reflecting the rapid changes in technology.
This funding not only underscores the increasing importance of AI in biopharma but also highlights Pharosyn's commitment to empowering pharmaceutical companies with the tools necessary for maintaining a competitive edge. As the industry continues to embrace digital transformation, platforms like Pharosyn could play a pivotal role in shaping future strategies and operational efficiencies.